Cargando…

Understanding potential participation barriers to improve trial design and outcomes: clinical trial simulation in palmoplantar pustulosis as a case study

OBJECTIVES: Evaluate the experiences and perceptions of patients participating in a simulated clinical trial and identify ways to enhance future patient-centric trial designs. DESIGN: International, multicentre, non-interventional, virtual clinical trial visits with patient debriefs and advisory boa...

Descripción completa

Detalles Bibliográficos
Autores principales: Boisvert-Huneault, Christian, Trigos Herraez, David, Pinter, Andreas, Kobayashi, Satomi, Bell, Stacie, Kallsen, Kimberley, Gloede, Tristan, Yagi, Nobutaka, Brunette, Steven, Datsenko, Yakov, Baehner, Frank, Clerisme-Beaty, Emmanuelle, Van de Kerkhof, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151841/
https://www.ncbi.nlm.nih.gov/pubmed/37094891
http://dx.doi.org/10.1136/bmjopen-2022-064159
_version_ 1785035628472172544
author Boisvert-Huneault, Christian
Trigos Herraez, David
Pinter, Andreas
Kobayashi, Satomi
Bell, Stacie
Kallsen, Kimberley
Gloede, Tristan
Yagi, Nobutaka
Brunette, Steven
Datsenko, Yakov
Baehner, Frank
Clerisme-Beaty, Emmanuelle
Van de Kerkhof, Peter
author_facet Boisvert-Huneault, Christian
Trigos Herraez, David
Pinter, Andreas
Kobayashi, Satomi
Bell, Stacie
Kallsen, Kimberley
Gloede, Tristan
Yagi, Nobutaka
Brunette, Steven
Datsenko, Yakov
Baehner, Frank
Clerisme-Beaty, Emmanuelle
Van de Kerkhof, Peter
author_sort Boisvert-Huneault, Christian
collection PubMed
description OBJECTIVES: Evaluate the experiences and perceptions of patients participating in a simulated clinical trial and identify ways to enhance future patient-centric trial designs. DESIGN: International, multicentre, non-interventional, virtual clinical trial visits with patient debriefs and advisory boards. SETTING: Virtual clinic visits and accompanying advisory boards. PARTICIPANTS: Nine patients with palmoplantar pustulosis for simulated trial visits; 14 patients and patient representatives for advisory boards. MAIN OUTCOME MEASURES: Qualitative responses to trial documentation, visit schedule and logistics, and trial design were collected during patient debriefs. Results were discussed at two virtual advisory board meetings. RESULTS: Patients identified key barriers to participation and potential difficulties encountered when attending trial visits and completing assessments. They also proposed recommendations to overcome these challenges. Patients recognised the need for comprehensive informed consent forms, but recommended use of non-technical language, brevity and additional support to aid understanding. Other trial documentations should be relevant to the disease and include known efficacy and safety of the study drug. Patients were concerned about receiving placebo, stopping existing medications and being unable to receive the study drug after trial completion; therefore, patients and physicians recommended an open-label extension following trial completion. Trial visits were too numerous (n=20) and too long (3–4 hours each); patients recommended improvements to the design to make best use of their time and reduce unnecessary waiting. They also requested financial and logistical support. Patients expressed a desire for study outcomes that matter to them, related to their ability to undertake normal daily activities and not be a burden to others. CONCLUSIONS: Simulated trials are an innovative method for assessing trial design and acceptance from a patient-centric perspective, enabling specific improvements to be made prior to trial initiation. Incorporation of recommendations from simulated trials could enhance trial recruitment and retention, and optimise trial outcomes and data quality.
format Online
Article
Text
id pubmed-10151841
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-101518412023-05-03 Understanding potential participation barriers to improve trial design and outcomes: clinical trial simulation in palmoplantar pustulosis as a case study Boisvert-Huneault, Christian Trigos Herraez, David Pinter, Andreas Kobayashi, Satomi Bell, Stacie Kallsen, Kimberley Gloede, Tristan Yagi, Nobutaka Brunette, Steven Datsenko, Yakov Baehner, Frank Clerisme-Beaty, Emmanuelle Van de Kerkhof, Peter BMJ Open Dermatology OBJECTIVES: Evaluate the experiences and perceptions of patients participating in a simulated clinical trial and identify ways to enhance future patient-centric trial designs. DESIGN: International, multicentre, non-interventional, virtual clinical trial visits with patient debriefs and advisory boards. SETTING: Virtual clinic visits and accompanying advisory boards. PARTICIPANTS: Nine patients with palmoplantar pustulosis for simulated trial visits; 14 patients and patient representatives for advisory boards. MAIN OUTCOME MEASURES: Qualitative responses to trial documentation, visit schedule and logistics, and trial design were collected during patient debriefs. Results were discussed at two virtual advisory board meetings. RESULTS: Patients identified key barriers to participation and potential difficulties encountered when attending trial visits and completing assessments. They also proposed recommendations to overcome these challenges. Patients recognised the need for comprehensive informed consent forms, but recommended use of non-technical language, brevity and additional support to aid understanding. Other trial documentations should be relevant to the disease and include known efficacy and safety of the study drug. Patients were concerned about receiving placebo, stopping existing medications and being unable to receive the study drug after trial completion; therefore, patients and physicians recommended an open-label extension following trial completion. Trial visits were too numerous (n=20) and too long (3–4 hours each); patients recommended improvements to the design to make best use of their time and reduce unnecessary waiting. They also requested financial and logistical support. Patients expressed a desire for study outcomes that matter to them, related to their ability to undertake normal daily activities and not be a burden to others. CONCLUSIONS: Simulated trials are an innovative method for assessing trial design and acceptance from a patient-centric perspective, enabling specific improvements to be made prior to trial initiation. Incorporation of recommendations from simulated trials could enhance trial recruitment and retention, and optimise trial outcomes and data quality. BMJ Publishing Group 2023-04-24 /pmc/articles/PMC10151841/ /pubmed/37094891 http://dx.doi.org/10.1136/bmjopen-2022-064159 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Dermatology
Boisvert-Huneault, Christian
Trigos Herraez, David
Pinter, Andreas
Kobayashi, Satomi
Bell, Stacie
Kallsen, Kimberley
Gloede, Tristan
Yagi, Nobutaka
Brunette, Steven
Datsenko, Yakov
Baehner, Frank
Clerisme-Beaty, Emmanuelle
Van de Kerkhof, Peter
Understanding potential participation barriers to improve trial design and outcomes: clinical trial simulation in palmoplantar pustulosis as a case study
title Understanding potential participation barriers to improve trial design and outcomes: clinical trial simulation in palmoplantar pustulosis as a case study
title_full Understanding potential participation barriers to improve trial design and outcomes: clinical trial simulation in palmoplantar pustulosis as a case study
title_fullStr Understanding potential participation barriers to improve trial design and outcomes: clinical trial simulation in palmoplantar pustulosis as a case study
title_full_unstemmed Understanding potential participation barriers to improve trial design and outcomes: clinical trial simulation in palmoplantar pustulosis as a case study
title_short Understanding potential participation barriers to improve trial design and outcomes: clinical trial simulation in palmoplantar pustulosis as a case study
title_sort understanding potential participation barriers to improve trial design and outcomes: clinical trial simulation in palmoplantar pustulosis as a case study
topic Dermatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151841/
https://www.ncbi.nlm.nih.gov/pubmed/37094891
http://dx.doi.org/10.1136/bmjopen-2022-064159
work_keys_str_mv AT boisverthuneaultchristian understandingpotentialparticipationbarrierstoimprovetrialdesignandoutcomesclinicaltrialsimulationinpalmoplantarpustulosisasacasestudy
AT trigosherraezdavid understandingpotentialparticipationbarrierstoimprovetrialdesignandoutcomesclinicaltrialsimulationinpalmoplantarpustulosisasacasestudy
AT pinterandreas understandingpotentialparticipationbarrierstoimprovetrialdesignandoutcomesclinicaltrialsimulationinpalmoplantarpustulosisasacasestudy
AT kobayashisatomi understandingpotentialparticipationbarrierstoimprovetrialdesignandoutcomesclinicaltrialsimulationinpalmoplantarpustulosisasacasestudy
AT bellstacie understandingpotentialparticipationbarrierstoimprovetrialdesignandoutcomesclinicaltrialsimulationinpalmoplantarpustulosisasacasestudy
AT kallsenkimberley understandingpotentialparticipationbarrierstoimprovetrialdesignandoutcomesclinicaltrialsimulationinpalmoplantarpustulosisasacasestudy
AT gloedetristan understandingpotentialparticipationbarrierstoimprovetrialdesignandoutcomesclinicaltrialsimulationinpalmoplantarpustulosisasacasestudy
AT yaginobutaka understandingpotentialparticipationbarrierstoimprovetrialdesignandoutcomesclinicaltrialsimulationinpalmoplantarpustulosisasacasestudy
AT brunettesteven understandingpotentialparticipationbarrierstoimprovetrialdesignandoutcomesclinicaltrialsimulationinpalmoplantarpustulosisasacasestudy
AT datsenkoyakov understandingpotentialparticipationbarrierstoimprovetrialdesignandoutcomesclinicaltrialsimulationinpalmoplantarpustulosisasacasestudy
AT baehnerfrank understandingpotentialparticipationbarrierstoimprovetrialdesignandoutcomesclinicaltrialsimulationinpalmoplantarpustulosisasacasestudy
AT clerismebeatyemmanuelle understandingpotentialparticipationbarrierstoimprovetrialdesignandoutcomesclinicaltrialsimulationinpalmoplantarpustulosisasacasestudy
AT vandekerkhofpeter understandingpotentialparticipationbarrierstoimprovetrialdesignandoutcomesclinicaltrialsimulationinpalmoplantarpustulosisasacasestudy